ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

This early-phase study tests AVZO-023 — an experimental CDK inhibitor (a drug that blocks cancer cell growth signals) — alone or with another experimental drug and/or hormone therapy in patients with advanced solid tumors, including breast cancer and other hormone-sensitive cancers. **You may be eligible if...** - You are 18 or older with a confirmed advanced solid tumor that has not responded to standard treatments - You are in reasonably good health (ECOG 0–1) - You have measurable disease or bone-only disease (in escalation phase) - Your kidney, liver, and bone marrow function are adequate **You may NOT be eligible if...** - You have previously received an experimental CDK2 or CDK4 inhibitor - You have active or untreated brain metastases - You have had recent anticancer therapy, major surgery, or radiation - You have a history of drug-induced lung inflammation (pneumonitis) - You have a known loss-of-function mutation in the Rb1 gene Talk to your doctor to see if this trial is right for you.